Bharathi Pulla, MD
Adolescent Medicine · Kenosha, WINPI 1962559302
Payments from drug & device makers
Across 481 payments — averaging $1652.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$289K
- Eli Lilly$264K
- Esperion Therapeutics, Inc.$78K
- Kowa Research Institute, Inc.$55K
- Pfizer$46K
- Boehringer Ingelheim International GmbH$22K
- plus $41K from 45 others
Across 5 payments — averaging $2034.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7K
- Eli Lilly$3K
What the payments were for
- Food & beverage$3,62997%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$123
How this compares
Too few adolescent medicine providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $85,691 |
| MounjaroTirzepatide | 37 | $46,809 |
| VraylarCariprazine Hcl | 22 | $42,932 |
| TrulicityDulaglutide | 16 | $29,403 |
| JanuviaSitagliptin Phosphate | 25 | $26,809 |
| LinzessLinaclotide | 36 | $24,591 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $19,735 |
| MyrbetriqMirabegron | 18 | $17,334 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,437 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,106 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $10,877 |
| EliquisApixaban | 18 | $9,333 |
| Aripiprazole | 34 | $8,923 |
| EntrestoSacubitril/Valsartan | 12 | $8,617 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $7,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $467 | $85,69165 claims |
| Lilly USA, LLCMounjaro, Trulicity | $221 | $76,21253 claims |
| AbbVieVraylar, Linzess, Synthroid | $365 | $68,73671 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $140 | $32,84143 claims |
| MerckJanuvia | $87 | $26,80925 claims |
| Astellas Pharma US IncMyrbetriq | $131 | $17,33418 claims |
| PfizerEliquis | $46,279 | $9,33318 claims |
| NovartisEntresto | $52 | $8,61712 claims |
| AstraZenecaSymbicort | $297 | $7,09220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adolescent medicine providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other adolescent medicine in Kenosha
- Ratidzai RiogaWauwatosa$2K
- Syed HasnainMilwaukee$443
- Alicia Idler-PerezMilwaukee$316
- Elizabeth HovelMilwaukee$177
- Brenda GrassFond du Lac$146
- Mary JayMilwaukee$60
- Mariano RosalesWaupun$37
- Amy AttwellWaukesha$27
- Sarah BrownWaukesha$27
- Thomas DuboisWaukesha$27
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.